{"schema_version":"1","generated_at":"2026-11-15T11:03:03.780Z","data_as_of":null,"url":"https://www.findmykol.com/kol/naftali-bechar","json_url":"https://www.findmykol.com/kol/naftali-bechar/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"naftali-bechar","name":"Naftali Bechar","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Indianapolis","state":"IN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1902887896","openalex":"A5071147915"},"summary":"Naftali Bechar is an Oncology physician. OpenAlex indexes 12 publications with 294 citations (h-index 6).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":12,"cited_by_count":294,"h_index":6,"latest_activity_year":2024,"source":"works"},"publications":{"total":12,"shown":5,"withheld":7,"matched_by":"OpenAlex author record","recent":[{"title":"600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)","year":2024,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2024.08.669","status":"verified"},{"title":"575P Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results","year":2024,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2024.08.644","status":"verified"},{"title":"Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC).","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.3579","status":"verified"},{"title":"P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)","year":2022,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2022.04.215","status":"verified"},{"title":"Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10","year":2012,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2012.42.4044","status":"verified"}],"source":"works"},"contact":{"address_1":"7229 CLEARVISTA DR","city":"Indianapolis","state":"IN","zip":"462561698","phone":"317-621-4300","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1902887896","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":7}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2013-05-15","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}